tiprankstipranks
Third Harmonic ‘further behind’ Celldex after discontinuation, says Guggenheim
The Fly

Third Harmonic ‘further behind’ Celldex after discontinuation, says Guggenheim

After Third Harmonic Bio (THRD) announced that the company has decided to discontinue the ongoing Phase 1b study of its investigational drug candidate THB001 after observing asymptomatic liver transaminitis in two trial subjects, Guggenheim analyst Yatin Suneja said the news "puts them even further behind" competitor Celldex (CLDX), which has treated more than 120 patients to date with barzolvolimab with no reported cases of transaminitis. Suneja, who continues to like barzo’s profile in chronic urticarias and sees Celldex as "the clear leader in the c-KIT space" with one less competitor, keeps a Buy rating on Celldex shares.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CLDX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles